Visus begins clinical program for presbyopia-correcting eye drop
Visus Therapeutics has started a clinical development program for an eye drop designed to restore loss of near vision due to presbyopia, according to a press release.
The program’s lead candidate, Brimochol, combines FDA-approved carbachol and brimonidine tartrate and has undergone five clinical studies investigating efficacy and safety. The most recent study, carried out in 57 patients, showed a statistically significant improvement of near visual acuity of five Jaeger lines or more for at least 12 hours. No headaches or browaches were reported.
Phase 2 trials are expected to begin in early 2021.
“The data also suggest that, unlike other combination drop candidates in this space, pivotal studies of Brimochol are expected to demonstrate that the individual drugs will contribute significantly to the overall effect of the combination product on near visual acuity,” co-founder Rhett Schiffman, MD, MS, MHSA, chief medical officer and head of research and development at Visus Therapeutics, said in the release.
Visus also announced it has formed a clinical advisory board, led by Eric D. Donnenfeld, MD.